FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Senators Urge FDA: Do More to Resolve Drug Shortages

[ Price : $8.95]

A bipartisan Senate letter urges FDA commissioner Robert Califf and HHS secretary Xavier Becerra to step up efforts to help resolv...

FDA Grants, Denies Parts of Microbiome Petition

[ Price : $8.95]

FDA grants one part and denies another part of a petition submitted by the Microbiome Therapeutic Innovation Group by publishing a...

Regeneron Files sBLA for Evkeeza in Young Children

[ Price : $8.95]

FDA accepts for priority review a Regeneron Pharmaceuticals supplemental BLA for Evkeeza (evinacumab-dgnb) as an adjunct to other ...

Voting Members Sought for Radiation Safety Panel

[ Price : $8.95]

Federal Register notice: FDA requests nominations for voting members to serve on CDRHs Technical Electronic Product Radiation Safe...

Draft Guide on Heartworm Drugs for Dogs

[ Price : $8.95]

Federal Register notice: FDA makes available draft guidance #276 entitled Effectiveness of Anthelmintics: Specific Recommendations...

2 Admit Role in $38 Million Compounding Fraud

[ Price : $8.95]

The Justice Department says the two owners of New Jersey-based Synergy Medical have admitted to participating in a conspiracy to c...

Congress Should Pass VALID Act on LDTs: Advocates

[ Price : $8.95]

The heads of two cancer advocacy organizations urge Congress to approve the VALID Act to regulate laboratory-developed tests offer...

Janssen Sues Amgen Over Stelara Biosimilar Plans

[ Price : $8.95]

Janssen files a patent infringement suit against Amgen and its plans to seek FDA approval and market a biosimilar copy of Janssens...

Merck in Keytruda Patent Dispute with Johns Hopkins

[ Price : $8.95]

Merck sues Johns Hopkins University in Maryland federal court over patents Hopkins obtained following a research collaboration wit...

Lillys Bebtelovimab Not Authorized in U.S.

[ Price : $8.95]

FDA says Lillys bebtelovimab is not authorized for use in any U.S. region because it is not active against two key Omicron subvari...